To detect the incidence of diabetes in patients with schizophrenia in Taiwan.
P eople with schizophrenia have a shorter lifespan than the general population, and, based on a systematic review, the mortality gap between patients with schizophrenia and the general population has worsened in recent decades. 1 Some reports have revealed that excess premature mortality in patients with schizophrenia arises from coronary heart disease, caused by several risk factors such as insulin resistance and diabetes, smoking, obesity, dyslipidemia, and hypertension. 2 Diabetes and its complications are, in general, major public health issues and have created a heavy health burden worldwide. The trend of increasing prevalence of diabetes has been noted in all ages, ethnic groups. and education levels and in both sexes. 3, 4 Several reports have revealed that the age-and sex-adjusted prevalence of diabetes in patients with schizophrenia is about 1.5 to 2 times as high as the general population. 5, 6 Compared with the general population, patients with schizophrenia experience a higher incidence of risk factors for diabetes such as obesity, hypertension, and hyperlipidemia. These are caused by sedentary lifestyle; low SES, with obstacles to having physical diseases diagnosed or seeking adequate treatment; higher substance or smoking rates; and weight gain or metabolic disruption caused by psychiatric medications during the course of lifelong illness. [7] [8] [9] [10] Surveys have also found increasing incidence rates of diabetes in the general population in Western countries during recent decades. [11] [12] [13] Diabetes incidence in the general US population is estimated to be 0.15% to 0.63%. [14] [15] [16] There have been various studies to investigate the incidence of diabetes in patients with schizophrenia, with incidence rates ranging from 0.44% to 4.4%. [17] [18] [19] [20] Several reports have revealed that the incidence of diabetes in patients with schizophrenia is 2-to 4-fold higher than in the general population. 21, 22 Past studies have explored the diabetes incidence in different areas of Taiwan. A community and cross-sectional investigation performed in central Taiwan in 1987-1988 and 1991-1992 revealed that the annual age-adjusted incidence of type 2 diabetes was around 1.8%. 23 Later, a 2-township fixed-cohort study conducted from 1990-1993 to 1993-1996 showed the age-adjusted incidence of type 2 diabetes was 0.89%. 24 Taiwan implemented an NHI program in March 1995, which offered comprehensive, unified universal health insurance to all citizens. The program covers outpatient service, inpatient care, Chinese medicine, dental care, childbirth, physical therapy, preventive health care, home care, and rehabilitation for chronic mental illness. As many as 96% of the people in Taiwan were in the NHI program in 2000, and the BNHI was contracted with 91% of medical institutions in Taiwan.
There has been no comprehensive study of the incidence of diabetes in patients with schizophrenia in Taiwan. In our study, we first compare the incidence of diabetes between patients with schizophrenia and the general population in 2000. Second, we investigate the incidence of newly diagnosed diabetes in people with schizophrenia from 2000 to 2005. Third, we examine the incidence of diabetes in people with schizophrenia regarding their antipsychotic use. Fourth, we analyze the risk factors for diabetes developing in people with schizophrenia.
Methods

Sample
The NHRI provided a database of 1 million randomly selected subjects for study. The NHRI's claims database includes ambulatory care, hospital inpatient care, dental services, and prescription drugs. There were no statistically significant differences in age, sex, and average insured payroll-related amount between the sample group and all enrollees. In our study, we excluded people who were diagnosed with diabetes before 2000 and drew a random sample of 617 068 subjects aged 18 years and older in 2000. This study was approved by the Institutional Review Board of Jianan Mental Hospital.
The Definition of Schizophrenia
The diagnosis of schizophrenia was coded according to the ICD-9-CM diagnostic criteria 25 in the NHI program in Taiwan. Study subjects were identified based on the following criteria: at least one service claim during 2000 for either ambulatory or inpatient care, with a primary diagnosis of schizophrenia (ICD-9-CM: 295). 26, 27 
The Definition of Incident Diabetes
Study subjects who had at least one service claim during 2000 for either ambulatory or inpatient care with a primary diagnosis of diabetes (ICD-9-CM: 250) or any medications for treatment of diabetes from 2000 to 2005, and with no diagnosis of diabetes before 2000, formed the group for incident diabetes.
The Incidence of Diabetes in Patients With Schizophrenia
Patients with schizophrenia without diabetes before 2000 were included in the fixed cohort study from 2000 to 2005. Subjects with new diabetes were referred to as incident case patients and we calculated the incidence for each year from 2000 to 
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The Categories of Antipsychotic Exposure
We defined antipsychotic exposure categories according to prescriptions before the incident diabetes. It appears that the association between antipsychotic medication and development of diabetes relates to the drug that the patient was receiving before the time of diagnosis of diabetes. Antipsychotic use was divided into FGA use (butyrophenone, phenothiazine, thioxanthene, and miscellaneous antipsychotics such as pimozide, loxapine, and sulpiride) and SGA use (clozapine, olanzapine, quetiapine, risperidone, ziprasidone, amisulpride, zotepine, and aripiprazole).
Measure
Information on demographic factors, including age, sex, insurance amount, region, and urbanicity, and on antipsychotic use, was obtained directly from the BNHI-insured people's files. Age was classified into 1 of 6 categories: 18 to 29 years, 30 to 39 years, 40 to 49 years, 50 to 59 years, 60 to 69 years, and 70 years and older. In NHI, the premiums of the most insured people are determined by the insured wage and premium rate. The insured wage is the insurance amount. The 
Statistical Analysis
To compare the demographic characteristics, including age, sex, insurance amount, region, and urbanicity, between subjects with schizophrenia and the general population, we analyzed the data by using chi-square tests. Moreover, the differences of diabetes incidence rates between patients with schizophrenia and the general population categorized by variables, including age groups, sex, insurance amount, region, and urbanicity, were tested by the logistic regression adjusted for the other covariates. Finally, a Cox regression model was used to detect risk factors of diabetes in patients with schizophrenia from 2000 to 2005. SAS, Version 9.1 (SAS Institute Inc, Cary, NC), was used to link and analyze the data. In our study, the significance level was set at 0.05. Table 1 shows incidence of diabetes in patients with schizophrenia and the general population in 2000. The 1-year incidence of diabetes in patients with schizophrenia was higher than in the general population (1.46% and 1.12%, respectively; OR 1.47; 95% CI 1.09 to 1.97). Compared with the general population, patients with schizophrenia showed a higher incidence of diabetes in the following groups: aged 18 to 29 years; females; an insurance amount more than US$1281; northern region residents; and urban area residents.
Results
The annual incidence of diabetes in patients with schizophrenia from 2000 to 2005 was 1.46%, 1.49%, 1.78%, 1.61%, 2.71%, and 2.04%, respectively. The average annual incidence of diabetes in patients with schizophrenia was 1.84% during 2000 to 2005.
Regarding antipsychotic exposure from 2000 to 2005, the cumulative incidence of diabetes in patients with schizophrenia with FGA (14.6%) was higher than those with SGA (7.7%). The cumulative incidence of diabetes in patients with clozapine, olanzapine, quetiapine, risperidone, ziprasidone, amisulpride, zotepine, and aripiprazole use were 9.6%, 8.3%, 4.3%, 7.5%, 1.9%, 15.4%, 8.5%, and 0%, respectively. Table 2 shows the Cox regression of factors associated with incidence of diabetes in patients with schizophrenia. Higher incidence was found in the groups aged 30 to 39 years, 40 to 49 years, 50 to 59 years, 60 to 69 years, and 70 years and older; in females; in patients with hypertensive disease; in patients with hyperlipidemia; and in residents of the northern area.
There was no significant difference associated with insurance amount and urbanicity in the incidence of diabetes in patients with schizophrenia. In addition, a lower incidence of diabetes was found in patients with schizophrenia using quetiapine or risperidone.
Discussion
Our study is the first to use population-based NHI data to examine the incidence of diabetes in patients with n/a = not applicable; -= reference category schizophrenia in Taiwan. Additionally, there have been no previous studies comparing the incidence of diabetes in patients with schizophrenia and in the general population in Taiwan. We found that patients with schizophrenia had 1.47 times higher risk of new diabetes than the general population in this study, which was similar to previous Western studies. 15, 16 During a 6-year period (2000 to 2005), our study indicated the mean annual incidence of diabetes was 1.84% in patients with schizophrenia. These results were also consistent with several Western studies. 14, 18 An increasing incidence rate of diabetes from 1.47% to 2.71% from 2000 to 2005, respectively, was found in our study. Why were more new cases of diabetes diagnosed year by year? First, after implementation of NHI programs, people with schizophrenia had greater access to treatment for medical diseases. Second, psychiatrists and other specialists had increased understanding of the comorbidities with schizophrenia, including diabetes and other medical diseases.
Regarding age, our study revealed a higher incidence of diabetes in the youngest age group of patients with schizophrenia than in the general population, which is similar to findings in other investigations. 14, 28 This may be attributable to several causes. First, schizophrenia itself seems to be an independent risk factor for diabetes. Mukherjee et al 29 found a higher rate of family history of diabetes among patients with schizophrenia. Also, Ryan et al 30 demonstrated a high rate of impaired fasting glucose tolerance and insulin resistance in first-episode, drugnaive patients with schizophrenia, compared with healthy subjects. Hypercortisolemia, resulting from overactivity of the hypothalamic-pituitary-adrenal axis that may lead to excessive visceral fat and strongly affects diabetes development, was also reported in patients with schizophrenia. 31 Therefore, genetic loading and neurohormone disturbance appear to play a critical role in these patients having diabetes. Second, schizophrenia usually occurs in the late teens or early 20s and is a chronic condition. Thus genetic vulnerability, as well as consequent negative effect on metabolic profiles by antipsychotic medication use, low physical activity, and poor self-care, all contribute to the earlier onset of diabetes in patients with schizophrenia than in the general population. In fact, increasing evidence suggests that children and adolescents using antipsychotics are much more likely to have metabolic problems than adults using the same drugs and dosages. 32 If a person receives a diagnosis of schizophrenia at an early age, clinicians should provide warnings about the possibility of diabetes occurrence and launch aggressive treatment programs.
According to our study, female patients with schizophrenia had a 1.51 times higher incidence rate of diabetes than the general female population. Meanwhile, female patients with schizophrenia had a higher incidence rate of diabetes than male patients with schizophrenia. Therefore, we should pay particular attention to female patients with schizophrenia for the prevention and treatment of diabetes. Although there are no definite conclusions about a relation between sex and diabetes incidence, 28 many studies have pointed out a sex difference in predisposition for diabetes or MeS. Additionally, women are reported to experience antipsychotic medication side effects, including body weight gain, hyperprolactinemia, and cardiac effects, more than men. 33 In a case-control analysis of antipsychotic-treated patients, women had a higher incidence of diabetes than men. 19 Several studies have reported disparities in visceral lipid distribution (indicating central obesity), pharmacokinetic profile of psychotropic agents associated with the hepatic cytochrome P-450 system, and some neurohormones related to weight regulation, such as leptin, between both sexes. These factors may place females at a higher risk of developing diabetes or associated metabolic problems. [33] [34] [35] According to one community study focusing on Hong Kong Chinese, the age-adjusted risk of having diabetes for subjects with the lowest SES was 2.3 to 2.5 times higher than those with the highest SES. 9 Our findings revealed that patients with schizophrenia at the highest SES had a higher diabetes incidence rate than the general population, but patients with lower SES did not show a higher diabetes incidence than the general population. This result may suggest that diabetes in people with a lower SES was underdiagnosed or undertreated in an NHI program. Patients with schizophrenia or their caregivers in lower SES groups may have poor knowledge of diabetes development and may not seek treatment. Subjects with schizophrenia do not need to make co-payments to receive psychiatric services; however, co-payment is required for diabetes treatment in Taiwan. Thus the equality of and access to medical treatment among patients with schizophrenia of different SES should be emphasized.
Regarding region, patients living in northern Taiwan had a higher diabetes incidence rate than the general population. Northern Taiwan is densely populated and possesses the most complete medical and welfare supports, compared with any other area of Taiwan, making it more convenient for patients with schizophrenia to seek medical treatment. A higher incidence of diabetes was also noted in patients with schizophrenia dwelling in urban areas than in the general population. To summarize, the results based on geography hint at differences in equality of, access to, and local features of treatment between locations or areas in Taiwan.
Antipsychotics played an important role for the pharmacotherapy for patients with schizophrenia. Our study revealed that patients on quetiapine and risperidone had a significantly lower diabetes incidence rate than those on an FGA. Additionally, the risk of newly developing diabetes was not different between clozapine, olanzapine, zotepine, and FGA. Although many surveys have pointed out that SGAs, especially olanzapine and clozapine, make people more prone to developing diabetes or related MeSs, findings have been inconsistent. 28, 36 In terms of clinical practice, both FGAs and SGAs possibly cause diabetes or MeS mediated by weight gain resulting from their effects on neurotransmitters or receptors. In our clinical experience, dysglycemia can develop as soon as a few months after antipsychotic treatment begins, before clinically obvious body weight gain and increased waist circumference. 37 According to the Cox regression analysis, we found that hyperlipidemia and hypertension were related to a higher incidence of diabetes in patients with schizophrenia, which was in line with previous studies. 28, 38 To our knowledge, age, hypertension, and poor lipid profiles are all associated with the onset of diabetes in the general population. 39 Moreover, patients with schizophrenia experience additional risk factors, including psychotropic medication use and higher smoking rates, and lack protective factors, such as regular exercise and healthy eating habits.
The results from the Clinical Antipsychotic Trials of Intervention Effectiveness (commonly referred to as CATIE) demonstrated that MeS is highly prevalent in patients with schizophrenia in the United States, causing significant health problems. 34 However, the nontreatment rate in the subjects with schizophrenia was 30.2% for diabetes, 62.4% for hypertension, and as high as 88% for dyslipidemia in a large-scale investigation in the United States. 40 In addition to detecting underlying disrupted metabolic profiles by regular laboratory surveys (blood pressure, sugar, and lipid levels) and measurements of waist circumference, aggressive pharmacological treatment are also needed for existing diabetes, hypertension, or hyperlipidemia. We should keep in mind that MeS is potentially reversible by choosing medications with less impact on metabolism, encouraging patients to be active, promoting programs to quit smoking, and to follow a healthy diet and so on.
The NHI database provided us with population-based, randomized claims information of insured people in Taiwan. In addition, the longitudinal data were much more effective for measuring the incidence of diabetes and correlates than other study methods such as cross-sectional field investigations or medical record surveys. Nevertheless, we must point out some limitations in our study. The reliability and validity of secondary data should be considered. We did not include other risk factors for diabetes, such as smoking, family history, body weight, or waist circumference. 16 There was insufficient information about the dosage and duration of antipsychotic use before the onset of incident diabetes. Patients could tend to receive different drugs over these years. Aside from antipsychotics, medications, as well as physical conditions related to diabetes onset, including mood stabilizers, steroids, and liver disease, were not available for our study.
Conclusions
Patients with schizophrenia had a higher incidence of diabetes for the youngest adult age group and for females than the general population. Increased age, females, hypertension, and hyperlipidemia were risk factors of diabetes in patients with schizophrenia. The relation between antipsychotic agents, physical diseases, and incidence of diabetes needs further comprehensive study.
